Brampton, Ontario-based Medtronic Canada said in a news release that Micra AV is indicated for treating patients with AV block, making it the first and only Health Canada-licensed leadless pacemaker portfolio. The pacemaker won FDA approval in the U.S. in January of this year.
The Micra system initially received FDA approval in 2016. The product is about the size of a vitamin pill and is mplanted inside the heart’s right ventricle via a catheter, eliminating the need to run leads to the heart.
Micra AV, the new version of the original platform, has the same size and shape as the original Micra system, but the device has additional features, including internal atrial sensing algorithms to detect cardiac movement, allowing the device to adjust pacing in the ventricle to coordinate with the atrium, Medtronic Canada said.
“Medtronic remarkably changed healthcare 63 years ago with the first battery-powered pacemakers, and we are proud to continue pioneering in the field of pacing by offering the first miniaturized, leadless pacing portfolio,” senior director of Medtronic Canada’s cardiovascular portfolio Mitch Leschuk said in the release. “Micra AV reinvents our own innovation, expanding the benefits of leadless pacemakers to more patients.”